Corcept Therapeutics | CORT - Operating Profit


Corcept Therapeutics reported $41.3M in Operating Profit for its fiscal quarter ending in June of 2026.





Operating Profit Change Date
Acadia Pharmaceuticals USD 37.84M 42.45M Jun/2026
Alaunos Therapeutics USD -1.01M 175K Mar/2026
ANI Pharmaceuticals USD 38.71M 9.58M Mar/2026
Ardelyx USD -32.79M 37.89M Mar/2026
Aurora Cannabis CAD -10.03M 25.76M Mar/2026
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Bristol-Myers Squibb USD 299M 3.07B Jun/2026
Canopy Growth CAD -27.47M 14.81M Mar/2026
Corcept Therapeutics USD 41.3M 90.9M Jun/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
J&J USD 7.48B 860M Jun/2026
Knight Therapeutics CAD 6.21M 3.27M Dec/2025
Lexicon Pharmaceuticals USD -14.78M 2.59M Dec/2025
Merck USD 840M 2.72B Jun/2026
Nektar Therapeutics USD -38.26M 19.17M Mar/2026
Novartis USD 4.75B 515M Jun/2026
Novartis USD 4.24B 171M Mar/2026
Omeros USD -35.41M 23.75M Sep/2024
Pacira USD 9.96M 5.33M Jun/2026
Pfizer USD 667M 4.32B Jun/2026
Supernus Pharmaceuticals USD -21.04M 14.21M Jun/2026
TG Therapeutics USD 21.67M 13.12M Jun/2026